A Revolutionary Treatment for OCD in Horses

the technology in a large cohort of human patients.
Levingstone says that Dr. John Gleeson SurgaColl CTO cofounder and coinventor of the technologies is very excited about the potential to translate the performance seen in animals into the human clinical setting. 
Dr. Gleeson has already seen SurgaColls first product HydroxyColl significantly improve patients outcomes firsthand she says quoting his response It is an amazing experience to be involved in the first stages of the invention of a novel medical implant device and then being fortunate enough to ultimately be in theatre with the operating surgeon and patient undergoing surgery and to see your product being implanted and making a meaningful impact on patients lives. It is an amazing privilege as a scientist.
Moving forward Levingstone says the next generation of technologies from Prof. OBriens lab is using materials like these but combining them with stem cells and gene therapy to target even more complex injuries that can lead to osteoarthritis.
It is clearly an exciting time to be in equine research and surgery. Horses today are able to benefit from many procedures that offer them so many options to live healthy competitive lives.